UBS/CALL/ASTRAZENECA ADR/90/0.1/19.12.25

UBS/CALL/ASTRAZENECA ADR/90/0.1/19.12.25 Share Price

DE000UM524Q6

Real-time Boerse Frankfurt Warrants 12:55:30 27/06/2024 pm IST
0.63 ^EUR	-4.55%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart UBS/CALL/ASTRAZENECA ADR/90/0.1/19.12.25

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	30/11	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	14/23/14	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	27/22/27	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	14/22/14	PR

More news

Quotes 5-day view

Date	Price	Change
27/24/27	0.63	-4.55%
26/24/26	0.66	-1.49%
25/24/25	0.67	-1.47%
24/24/24	0.68	+3.03%
21/24/21	0.66	+3.13%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 12:55 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	UBS
WKN	UM524Q
ISIN	DE000UM524Q6
Date issued	10/06/2024
Strike	90 $
Maturity	19/12/2025 (541 Days)
Parity	10 : 1
Emission price	0.65 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.73 €
Lowest since issue	0.6 €
Delta	0.45x
Omega	4.707
Premium	23.28x
Gearing	10.56x
Moneyness	0.8787
Difference Strike	10.92 $
Difference Strike %	+12.13%
Spread	0.08 €
Spread %	10.81%
Theoretical value	0.6700
Implied Volatility	26.79 %
Total Loss Probability	66.91 %
Intrinsic value	0.000000
Present value	0.6700
Break even	97.16 €
Theta	-0.01x
Vega	0.03x
Rho	0.04x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company